From the earliest days of COVID-19, King & Spalding has been at the forefront of vaccine developments, helping our leading pharmaceutical clients develop and implement strategies to contain the legal and reputational risks throughout their journey. At this critical juncture of distribution, our COVID-19 Vaccine Rollout Task Force is drawing on our industry knowledge and client relationships to serve as a guiding light and partner to our clients.
As you will see in the resources herein, we are focused on untangling the matrix of hurdles that arise in this unchartered landscape of developing state guidance intersecting with a rapidly evolving federal landscape. We are also examining the legislation developing to advise clients on immunity provisions and helping our clients prepare for potential investigations and litigation to follow.
This survey provides COVID-19 vaccine status, guidance, laws and regulations, and other legal developments.Read More
This blog provides regular updates on COVID-19 vaccine-related developments.Read More
In response to the ongoing COVID-19 pandemic, the U.S. government, many states, and even some counties and municipalities have invoked emergency powers and issued a variety of executive-level orders to protect the public health.Read More
Mandatory Employee Vaccinations Globally: Can You Require Your Employees To Get The COVID-19 Vaccine Everywhere?Read More
September 27, 2021
Dan Hettich and Ahsin Azim comment on HRSA’s COVID-19 claims reimbursement to healthcare providers and facilities for testing, treatment, and vaccine administration for the uninsured